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Toward a Better Understanding of...

CIViC: Bridging the Gap between Clinical
Treatment and Cancer Research
Kaitlin A. Clark
Mentor: Malachi Griffith
Precision, or personalized, medicine seeks to tailor clinical treatment based on each
person’s genomic makeup. In the context of cancer, this often involves modifying disease
treatment based on the presence and absence of known cancer-causing mutations.
The biomedical literature describing these associations is huge. But, currently, the
publications explaining genotype-phenotype correlations exist largely in private or
encumbered databases resulting in extensive repetition of effort and lack of public
access to clinically-actionable data, which in turn reduces the effectiveness of precision
medicine. Realizing the potential power of precision medicine requires this information
be centralized, vetted and interpreted for clinical application and public access.
The Clinical Interpretations of Variants in Cancer (CIViC) project aims to enable
precision medicine by providing an open access knowledgebase for clinicians,
researchers, and patients to input submission data, vet this information, and learn about
the clinical significance of cancer genome alterations.
My project focusing on curating information on the VHL gene, which, when
mutated, causes von Hippel-Lindau disease, is underway. Von Hippel-Lindau disease
(VHLD) is a rare, autosomal dominant disease affecting 1 in 36,000 people worldwide
and manifests as hemangioblastomas of the central nervous system and retina, renal cell
carcinomas, and pheochromocytomas. I seek to curate a large and growing dataset on
VHL gene alterations, VHLD, and VHLD patient outcomes in order to link actionable
genetic data to clinical practice. Specifically using the CIViC platform, I will summarize
patient genotypes, their related phenotypes, and any findings for better prognosis and/or
diagnosis of VHLD for each available publication.
From the curation of this information, we hope to create a more comprehensive and
readily accessible understanding of the clinical relevance of VHL gene variants and their
impact on disease phenotype and treatment, taking us a step closer to realizing the power
of precision medicine.
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